MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202527125934 A) filed by Sun Pharmaceutical Industries Limited on December 12, 2025, for Glp-1/Gip Dual, Glp-1/Gcg Dual And Glp-1/Gip/Gcg Triple Receptor Agonists.
Inventors include Thennati, Rajamannar; Burade, Vinod Sampatrao; Natarajan, Muthukumaran; Joshi, Dhiren Rameshchandra; Gandhi, Manish Harendraprasad; Jivani, Chandulal Thakarshiibhai; Tiwari, Abhishek; Soni, Krunal Harishbhai; Maru, Alpeshbhai Balabhai; Dixit, Pankaj Vinodrao; Pateliya, Bharatbhai Balabhai; and Nagaraja, Ravishankara Madavati.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: The present invention relates to GLP-1/GIP/GCG triple receptor agonists and use thereof in the treatment or prevention of Type 2 diabetes mellitus (T2DM), hyperlipidemia/dyslipidemia, metabolic syndromes, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), neurodegenerative disorders, fibrosis, cardiovascular risks, and/or obesity.
Disclaimer: Curated by HT Syndication.
